Iobenguane sulfate NEW
| Price | $64 | $93 | $218 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Iobenguane sulfate | CAS No.: 87862-25-7 |
| Purity: 99.04% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Iobenguane sulfate |
| Description | Iobenguane sulfate (MIBG sulfate) is a high-affinity substrate for cholera toxin that disrupts cellular mono(ADP-ribosylation). Radioiodinated Iobenguane sulfate is used clinically as a tumor-targeted radiopharmaceutical for diagnosing and treating adrenergic tumors. |
| In vitro | Iobenguane sulfate is an effective effector of endogenous mono(ADP-ribosyl) transferases of turkey and human erythrocyte membranes, exerting its effect in the μM concentration range. Iobenguane sulfate (2-20 μg/ml; 72 hours) suppresses cell growth in a panel of human and mouse leukemia, melanoma, fibrosarcoma, and neuroblastoma cell lines. |
| In vivo | Iobenguane sulfate (20 mg/kg; i.p.; daily on days 3-6) displays antitumor activity. Iobenguane sulfate testes for its toxicity on male strain AF (N1Ell5) mice with 5 daily injections. At 50 mg/kg body weight, all animals died after 1-4 doses and 4/16 animals died on a schedule of 44 mg/kg. The survival of male strain AF mice inoculates with N1E115 neuroblastoma and treats according to NIH protocols for new drug testing with 9 daily injections of Iobenguane sulfate (40 mg/kg), Marking prolongation of survival but no cures were observed. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (308.52 mM), Sonication is recommended. |
| Keywords | proliferation | survival | tumors | MIBG | Iobenguane | mono(ADP-ribosylation) | Iobenguane sulfate | inhibit | cytotoxic | Iobenguane Sulfate | analogue | antitumor | Inhibitor | MIBG Sulfate | adrenergic |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/1kg |
Hebei Jingbo New Material Technology Co., Ltd
|
2023-12-18 | ||
| $27.00/1KG |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY